October 21, 2021 -- Johnson & Johnson and Moderna have received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for booster shots of their COVID-19 vaccines.
Johnson & Johnson COVID-19 vaccine booster shots are authorized for adults ages 18 and older at least two months following primary vaccination and for eligible individuals who received a different authorized or approved COVID-19 vaccine.
The Johnson & Johnson booster shot will be the same formulation and dosage as the primary shot. The company has a sufficient supply to support boosting in the U.S. for all those who received primary vaccination with the Johnson & Johnson COVID-19 vaccine, the company said.
Moderna's EUA covers the use a booster dose of its COVID-19 vaccine (mRNA-1273) at the 50 µg dose level for people ages 65 and older, people ages 18 to 64 who are at high risk of severe COVID-19, and people ages 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2.
Moderna's booster dose is to be administered at least six months after completion of a primary series and is also authorized for people who completed a primary vaccination with other authorized or approved COVID-19 vaccines.
The U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices was expected meet on October 21 to provide a potential recommendation on the rollout of COVID-19 boosters.